...
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
【24h】

Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?

机译:NSCLC和病理学中的精密医学:ALK如何适应该途径?

获取原文
获取原文并翻译 | 示例
           

摘要

The evolution of personalised medicine in lung cancer has dramatically impacted diagnostic pathology. Current challenges centre on the growing demands placed on small tissue samples by molecular diagnostic techniques. In this review, expert recommendations are provided regarding successful identification of anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Steps to correctly process and conserve tumour tissue during diagnostic testing are essential to ensure tissue availability. For example, storing extra tissue sections ready for molecular diagnostic steps allows faster testing and preserves tissue. Fluorescence in situ hybridisation (FISH) is commonly used to detect ALK rearrangements, with most laboratories favouring screening by immunohistochemistry followed by a confirmatory FISH assay. Reverse transcription-polymerase chain reaction can also identify ALK fusion gene mRNA transcripts but can be limited by the quality of RNA and the risk that rare fusion variants may not be captured. Next-generation sequencing (NGS) technology has recently provided an alternative method for detecting ALK rearrangements. While current experience is limited, NGS is set to become the most efficient approach as an increasing number of genetic abnormalities is required to be tested. Upfront, reflex testing for ALK gene rearrangement should become routine as ALK tyrosine kinase inhibitor therapy moves into the first-line setting. Guidelines recommend that EGFR and ALK tests are carried out in parallel on all confirmed and potential adenocarcinomas, and this is more efficient in terms of tissue usage and testing turnaround time for both of these actionable gene alterations. The practice of sequential testing is not recommended. Identification of ALK rearrangements is now essential for the diagnosis of NSCLC, underpinned by the benefits of ALK inhibitors. As scientific understanding and diagnostic technology develops, ALK testing will continue to be an evolving and challenging paradigm.
机译:肺癌中个性化医学的发展已极大地影响了诊断病理学。当前的挑战集中在通过分子诊断技术对小型组织样品提出的日益增长的需求上。在这篇综述中,就成功鉴定间变性淋巴瘤激酶(ALK)重排的非小细胞肺癌(NSCLC)提供了专家建议。在诊断测试过程中正确处理和保存肿瘤组织的步骤对于确保组织的可用性至关重要。例如,存储准备用于分子诊断步骤的多余组织切片可以更快地进行测试并保存组织。荧光原位杂交(FISH)通常用于检测ALK重排,大多数实验室倾向于通过免疫组化和随后的FISH测定进行筛选。逆转录-聚合酶链反应也可以鉴定ALK融合基因的mRNA转录物,但可能受RNA质量和稀有融合变体无法捕获的风险的限制。下一代测序(NGS)技术最近提供了一种检测ALK重排的替代方法。尽管目前的经验有限,但由于需要测试越来越多的遗传异常,因此NGS必将成为最有效的方法。随着ALK酪氨酸激酶抑制剂治疗进入一线治疗,对ALK基因重排的反射测试应成为常规方法。指南建议对所有已确诊和潜在的腺癌同时进行EGFR和ALK检测,这在组织使用和这两种可行基因改变的检测周转时间方面均更为有效。不建议进行顺序测试。现在,以ALK抑制剂的优势为基础,鉴定ALK重排对于NSCLC的诊断至关重要。随着科学理解和诊断技术的发展,ALK测试将继续成为一个不断发展和具有挑战性的范例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号